8-K: Regeneron Pharmaceuticals Anticipates $24 Million IPR&D Charge Impacting Q2 2024 Earnings

Regeneron Pharmaceuticals expects a $24 million pre-tax charge related to acquired in-process research and development to negatively impact its second quarter 2024 earnings by approximately $0.18 per diluted share.

Summary

• Regeneron Pharmaceuticals anticipates a pre-tax charge of approximately $24 million related to acquired in-process research and development (IPR&D) for the second quarter of 2024.
• This charge stems from up-front payments and premiums on equity securities purchased in connection with collaboration and licensing agreements.
• The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by about $0.18 for the quarter.
• Regeneron does not typically forecast these IPR&D charges due to the unpredictable nature of these transactions.
• The company's second quarter 2024 results are preliminary and subject to finalization, with actual results potentially differing from these estimates.

Sentiment

Score: 6

Explanation: The document is neutral to slightly negative due to the expected negative impact on earnings, but this is a normal part of the business and not unexpected.

Negatives

• The $24 million IPR&D charge will negatively impact Regeneron's Q2 2024 earnings.
• The charge is expected to reduce net income per diluted share by approximately $0.18.

Risks

• The actual financial results for Q2 2024 may differ from the preliminary estimates.
• The timing and magnitude of future IPR&D charges are uncertain and difficult to predict.
• The company's non-GAAP financial measures may not be comparable with those of other companies.

Future Outlook

The company does not provide specific guidance on future IPR&D charges due to their unpredictable nature. The company cautions that actual results may differ from preliminary estimates.

Management Comments

• Management uses non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions.
• Management believes non-GAAP measures provide investors with an enhanced understanding of the financial performance of the company's core business operations.

Industry Context

IPR&D charges are common in the pharmaceutical industry due to the nature of drug development and licensing agreements. These charges can fluctuate significantly based on the timing and size of acquisitions and collaborations.

Comparison to Industry Standards

• IPR&D charges are a common occurrence in the pharmaceutical industry, particularly for companies engaged in active research and development and licensing activities.
• Companies like AbbVie, Amgen, and Gilead Sciences also frequently report IPR&D charges related to acquisitions and collaborations.
• The magnitude of these charges can vary significantly based on the specific deals and the stage of development of the acquired assets.
• Regeneron's $24 million charge is relatively modest compared to some larger acquisitions seen in the industry, but it is still a notable item impacting quarterly earnings.

Stakeholder Impact

• Shareholders will see a reduction in earnings per share due to the IPR&D charge.
• Investors should be aware of the potential for fluctuations in earnings due to these types of charges.

Next Steps

• Regeneron will finalize its financial results for the second quarter of 2024.
• The company will report its final Q2 2024 results, which may differ from the preliminary estimates.

Key Dates

Keywords

IPR&D, Acquired In-Process Research and Development, Regeneron, Financial Results, Earnings, GAAP, Non-GAAP, Collaboration Agreements, Licensing Agreements